（於開曼群島註冊成立的有限公司） （股份代號：6969） (Incorporated in the Cayman Islands with limited liability) (Stock code: 6969) SMOORE INTERN ATIONAL HOLDINGS LIMITED 思 摩 爾 國 際 控 股 有 限 公 司 INTERIM REPO RT 中 期 報 告 2025 目 錄 | 公司信息 | 2 | | --- | --- | | 主席報告 | 4 | | 財務摘要 | 8 | | 管理層討論與分析 | 10 | | 其他資料 | 33 | | 簡明綜合財務報表審閱報告 | 53 | | 簡明綜合損益及其他全面收益表 | 54 | | 簡明綜合財務狀況表 | 55 | | 簡明綜合權益變動表 | 57 | | 簡明綜合現金流量表 | 58 | | 簡明綜合財務報表附註 | 60 | 公司信息 董事會 執行董事 陳志平先生 （主席兼總裁） 熊少明先生 王貴升先生 王鑫女士 非執行董事 江敏女士 獨立非執行董事 鍾山先生 閻小穎先生 王高博士 審核委員會 鍾山先生 （主席） 閻小穎先生 ...

Core Viewpoint - The company is leveraging its R&D advantages to launch HNB products, aiming to capitalize on new industry trends and recover from previous regulatory challenges [1] Company Overview - Smoore International possesses strong R&D capabilities, particularly in ceramic core technology, and has established deep partnerships with major global tobacco companies [1] - The company is transitioning its business model from a device supplier to a tobacco business, opening new growth avenues with the launch of HNB products in collaboration with British American Tobacco [1][2] Industry Insights - The HNB segment is expected to accelerate its development, with a low penetration rate of approximately 6% in 2024, indicating significant growth potential [2] - The global traditional tobacco sales are declining, making new tobacco products a viable solution for market recovery, with 2025 anticipated as a pivotal year for major international tobacco companies [2] Market Dynamics - The HNB market is currently in a phase where supply is creating demand, with potential for increased penetration in large markets like the U.S. and China [2] - If HNB penetration in the U.S. reaches 15%, it could correspond to an incremental market size of $19.9 billion and a sales volume of 49.7 billion sticks [2] Product Development - The collaboration between Smoore and British American Tobacco on the Glo Hilo product combines their strengths, with Glo Hilo expected to compete effectively against Philip Morris's IQOS [2] - The latest Glo Hilo product features a quick preheating time of 3-5 seconds and high flavor fidelity, significantly enhancing consumer experience [2] Financial Projections - Revenue sharing for Glo Hilo is projected to be in the single to double-digit percentage range, with expected earnings per stick ranging from 0.04 to 0.11 RMB [2] - If HNB penetration increases to 12% and Glo Hilo market share reaches 25%, Smoore's annual profits from HNB could reach 6 to 7 billion RMB [2] Traditional Business Outlook - The U.S. vaping market is expected to grow from $19.81 billion in 2021 to $27.03 billion in 2024, with a CAGR of 11% [3] - Positive changes in the industry include FDA approvals for new flavors and increased enforcement against illegal products, which may benefit Smoore's vaping business [3] Long-term Strategy - The company is diversifying into medical and beauty vaping, along with special-purpose vaping, to build a sustainable future [3]

Investment Rating - The investment rating for the company is "Buy" and is maintained [12] Core Insights - Smoore International is the largest electronic vaporizer supplier globally, with growth potential unlocked by its technology positioning in HNB (Heated Not Burn) products [3][6] - The company's core business is recovering, benefiting from regulatory shifts in the industry and increasing market share among major clients [3][6] - The HNB business is expected to see significant growth, with a projected annual growth rate in the double digits and a current global penetration rate of less than 6% [3][7] Summary by Sections Introduction - Smoore International leverages its R&D advantages to launch HNB products, marking a new phase in the industry [6][17] - The company has transitioned from a pure equipment supplier to a tobacco business model, opening new growth avenues [6][17] Core Business - The HNB segment is poised for accelerated development, with a low penetration rate and high barriers to entry, indicating substantial growth potential [7][28] - The collaboration with British American Tobacco to launch Glo Hilo combines both companies' strengths, enhancing market competitiveness [7][28] Performance Outlook - The revenue-sharing model for Glo Hilo is expected to yield significant profits, with projections estimating annual profits for Smoore's HNB business to reach 6-7 billion RMB if market penetration increases [8][9] - The U.S. market presents a significant opportunity, with potential market size increases if HNB penetration rises to 15% [8][37] Traditional Business - The U.S. vaping market is expected to grow from $19.81 billion in 2021 to $27.03 billion in 2024, with a CAGR of 11% [9][20] - Regulatory changes in the U.S. are becoming more favorable, allowing for a recovery in the vaporizer business [9][20] Long-term Strategic Direction - The company is diversifying into medical and beauty vaporization, aiming for long-term growth across multiple sectors [10][19]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 思摩爾國際控股有限公司 (於開曼群島註冊成立的有限公司) FF301 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.01 USD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.01 USD | | 100,000,00 ...

Group 1 - Citi has lowered the target price for Smoore International to HKD 21, maintaining an "Outperform" rating [1] - UBS has also reduced the target price for Smoore International to HKD 13.11, while maintaining a "Sell" rating [1]

Core Viewpoint - Citi has released a report predicting that Smoore International (06969) will experience a 44% year-on-year decline in net profit and a 7% decline in adjusted net profit for this year, with a recovery expected between 2026 and 2027 [1] Financial Performance - The company reported an 18% year-on-year increase in sales for the first half of the year, while net profit fell by 28% and adjusted net profit decreased by 2%, aligning with earlier profit warnings [1] - The decline in net profit is primarily attributed to a significant drop in sales in China and a decrease in gross margin due to product mix adjustments [1] Future Projections - The firm anticipates a gross margin of 36.4% for this year, improving to 38.8% next year [1] - From 2025 to 2027, the company is expected to achieve a compound annual growth rate (CAGR) of 16% in sales and 48% in adjusted net profit [1] Market Dynamics - Sales this year are expected to be driven mainly by capsule products, following the EU's ban on single-use e-cigarettes and the expansion of advanced personal vaporizers (APV) and heated non-combustible (HNB) products [1] Investment Strategy - The management indicated that this year will be an investment year, with an additional investment of 300 million RMB planned for research and development in medical and heated non-combustible products [1]

Core Viewpoint - Citi has lowered the target price for Smoore International (06969) to HKD 21, maintaining an "outperform" rating, anticipating a 44% decline in net profit and a 7% drop in adjusted net profit for this year, with recovery expected in 2026-2027 [1] Financial Performance - The company reported an 18% year-on-year increase in sales for the first half of the year, while net profit fell by 28% and adjusted net profit decreased by 2%, aligning with earlier profit warnings [1] - The expected gross margin for this year is 36.4%, with an increase to 38.8% projected for next year [1] Future Projections - The firm anticipates a compound annual growth rate (CAGR) of 16% in sales and 48% in adjusted net profit from 2025 to 2027 [1] - Sales in the current year are expected to be primarily driven by capsule products, following the EU's ban on single-use e-cigarettes and the expansion of advanced personal vaporizers (APV) and heated non-combustible (HNB) products [1] Investment Strategy - Management has indicated that this year will be an investment year, with an additional RMB 300 million allocated for research and development in medical and heated non-combustible products [1]

Group 1 - The core viewpoint is that Smoore International (06969) has experienced a significant decline in net profit for the first half of the year, primarily due to increased R&D expenses and other costs, leading to a drop in stock price [1][2] - For the first half of the year, Smoore International reported revenue of 6.013 billion RMB, an increase of 18.3% year-on-year, while adjusted net profit was 737 million RMB, a decrease of 2.1%, and net profit was 492 million RMB, down 27.96% [1] - The company declared an interim dividend of 0.20 HKD per share, compared to 0.05 HKD per share in the same period last year [1] Group 2 - UBS reported that the decline in net profit was largely due to increased stock-based compensation, rising sales and development expenses, and a higher tax rate [2] - Management remains optimistic about revenue growth in the second half of the year, citing favorable policies for e-cigarettes in the US and Europe, although short-term profitability will still be impacted by R&D expenses [2] - UBS has lowered its earnings forecast for the company from 10% to 33% for the years 2023 to 2027, reflecting higher sales, marketing, and R&D expenditures, and has reduced the target price from 14 HKD to 13.11 HKD while maintaining a "sell" rating [2]

Core Viewpoint - Smoore International (06969) experienced a significant decline in stock price following its interim results, with a drop of over 6% in early trading and a current price of 19.23 HKD, despite a revenue increase of 18.3% year-on-year [1] Financial Performance - The company reported a revenue of 6.013 billion RMB for the first half of the year, reflecting an 18.3% increase year-on-year [1] - Adjusted net profit for the period was 737 million RMB, a decrease of 2.1% year-on-year [1] - The overall profit for the period was 492 million RMB, down 27.96% year-on-year [1] - The interim dividend declared was 0.20 HKD per share, compared to 0.05 HKD per share in the same period last year [1] Analyst Insights - Bank of America noted that Smoore's performance was generally in line with expectations, predicting a slight improvement in annual revenue growth, but continued pressure on profit margins [1] - UBS reported that the decline in net profit was primarily due to increased stock-based compensation, higher sales and development expenses, and a rising tax rate [1] - Management expressed optimism for continued revenue growth in the second half, supported by favorable policies for e-cigarettes in the US and Europe, although short-term profitability will be impacted by increased R&D spending [1] - The company is preparing to launch its own products in the US, with specific financial results from new business segments expected to be reflected by 2027 [1] - UBS downgraded its earnings forecast for the company from 10% to 33% for the years 2023 to 2027, citing higher sales, marketing, and R&D expenses, and lowered the target price from 14 HKD to 13.11 HKD, maintaining a "sell" rating [1]

Investment Rating - The investment rating for the company is "Outperform the Market" [7] Core Views - The company's revenue for the first half of 2025 reached 6.013 billion HKD, representing a year-on-year increase of 18.3%, while adjusted profit slightly decreased by 2.1% to 737 million HKD [1] - The company is benefiting from the global trend towards regulatory compliance, with its vaping business recovering as expected [1] - The company plans to distribute an interim dividend of 0.20 HKD per share [1] Revenue and Profit Analysis - The company's To B business revenue increased by 19.5% year-on-year to 4.74 billion HKD, with European revenue growing by 38.0% to 2.73 billion HKD [2] - In the U.S., revenue was 1.5% higher at 1.89 billion HKD, while domestic revenue decreased by 6.1% to 120 million HKD [2] - The self-owned brand business revenue grew by 14.1% year-on-year to 1.27 billion HKD, with European revenue increasing by 15.1% [3] Long-term Growth Potential - The successful commercialization of HNB products and steady progress in vaping medical applications are expected to drive long-term growth [3] - The company launched high-end HNB products in Japan, with plans for nationwide expansion and entry into more key markets in the second half of 2025 [3] Financial Forecasts - The profit forecast for 2025-2027 has been adjusted, with expected net profits of 1.239 billion HKD, 1.822 billion HKD, and 2.565 billion HKD respectively, reflecting year-on-year changes of -4.9%, +47.0%, and +40.8% [4] - The diluted EPS is projected to be 0.20, 0.29, and 0.41 HKD for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 98, 67, and 48 [4]